Clinical Trial ProgressPhase 3 CSU studies for barzo are expected to begin, reflecting positive momentum in the drug's development.
Drug EfficacyBarzolvolimab shows promising efficacy and safety in treatment of chronic spontaneous urticaria, setting the stage for becoming a therapy of choice.
Financial StabilityCelldex ended the year financially strong, with significant cash reserves to fund ongoing operations and research.